drugset
Drugs / pGM169/GL67A
last change Dec 2010 re-read 3 minutes ago

pGM169/GL67A

Other / unclassified targets CFTR

Developed for
cystic fibrosis
Investigated by
Cystic Fibrosis Trust · Imperial College London · Royal Brompton & Harefield NHS Foundation Trust · University of Edinburgh · University of Oxford · University of Pennsylvania

Trials 1

today NCT00789867 · Ph 1/2
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00789867 Nov 2008 → Aug 2009 cystic fibrosis Imperial College London Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as pGM169/GL67A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00789867 ↗
Modality Other / unclassified “single dose of non-viral CFTR gene therapy (pGM169/GL67A)” NCT00789867 ↗
Route Inhaled “Received a nebulized dose via an breath-actuated nebulizer” NCT00789867 ↗
Target CFTR “single dose of non-viral CFTR gene therapy (pGM169/GL67A)” NCT00789867 ↗